Skip to main content
SpringerLink
Log in

Carcinoid Tumors

  • Chapter
  • First Online:
Surgical Oncology

  • 3446 Accesses

Abstract

Carcinoid tumors are neoplasms derived from neuroendocrine cells and are widely distributed throughout the body in almost any organ. The traditional classification of carcinoid tumors includes foregut tumors with primaries located in the lung, stomach, or proximal duodenum, as well as the thymus; midgut tumors arising from the jejunum, ileum and proximal colon (appendix); and hindgut carcinoids (originating in the distal part of the colon and rectum. Foregut derivatives (except for the pharynx, the respiratory tract, and most of the esophagus) are mainly based on the celiac artery, midgut derivatives are based on the superior mesenteric artery, and hindgut derivatives are supplied by the inferior mesenteric artery.

Carcinoid tumors, while observed in approximately 1 % of appendectomy specimens, are the most common tumor of the vermiform appendix. The most common locations for carcinoid tumors are the appendix and distal ileum, followed by stomach, bronchopulmonary, and rectal. Carcinoid tumors produce a number of biologically active substances such as chromogranin A and 5-HIAA, which can be measured and used for diagnostic purposes. Octreoscan is the most widely used imaging modality for carcinoid.

An appendectomy is the treatment for appendiceal tumors less than 2 cm in diameter, whereas a right hemicolectomy is indicated for larger or more aggressive tumors. The general principle of surgical resection for tumors in other locations includes complete resection of the tumor with lymphadenectomy of the regional lymph nodes. Tumor debulking may play a palliative role in selected patients. Liver resection and transplantation have been shown to have excellent long-term survival for patients with isolated, resectable hepatic metastasis.

Overall prognosis is greater than 80 % after 10 years for appendiceal carcinoid tumors that had no evidence of metastatic disease. Carcinoid tumors of the small bowel have an overall 5-year survival rate of 50–60 %. Bronchial carcinoids can be of either typical or atypical histology and carry a 5-year survival rate of almost 90 % if typical but only 60 % for atypical subtypes. Foregut carcinoids of the stomach are divided by type with types 1 and 2 having an almost 100 % 5-year survival rate while type 3 tumors carry a 50 % 5-year survival rate and type 4 are often unresectable and carry the worst prognosis. Hindgut colorectal carcinoid tumors tend to be diagnosed later than small bowel carcinoid tumor and are associated with a worse prognosis; its 5-year survival rate is 40–50 %.

Somatostatin analogs are the mainstay of medical therapy for patients with advanced disease. Systemic chemotherapy has not shown benefit over treatment with somatostatin analogs alone; however, novel agents such as radiolabeled somatostatin analogs and bevacizumab have shown promise as adjuvant treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–29.

    PubMed  CAS  Google Scholar 

  2. Woods HF, Bax ND, Ainsworth I. Abdominal carcinoid tumours in Sheffield. Digestion. 1990;45 Suppl 1:17–22.

    PubMed  Google Scholar 

  3. Lu Cortez L, Clemente C, Puig V, Mirada A. Carcinoid tumor. An analysis of 131 cases. Rev Clin Esp. 1994;194(4):291–3.

    PubMed  CAS  Google Scholar 

  4. Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21(2):270–8.

    PubMed  CAS  Google Scholar 

  5. Chandrasegaram MD, Rothwell LA, An EI, Miller RJ. Pathologies of the appendix: a 10-year review of 4670 appendicectomy specimens. ANZ J Surg. 2012;82(11):844–7.

    PubMed  Google Scholar 

  6. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum. 1998;41(1):75–80.

    PubMed  CAS  Google Scholar 

  7. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol. 1998;93(3):422–8.

    PubMed  CAS  Google Scholar 

  8. Deans GT, Spence RA. Neoplastic lesions of the appendix. Br J Surg. 1995;82(3):299–306.

    PubMed  CAS  Google Scholar 

  9. Moertel CL, Weiland LH, Telander RL. Carcinoid tumor of the appendix in the first two decades of life. J Pediatr Surg. 1990;25(10):1073–5.

    PubMed  CAS  Google Scholar 

  10. Lubarsch O. Uber den pimaeren krebs des ileum nebst Bemerkungen ueber das gleichzeitige Vorkommen von krebs und Tuberculos. Virchows Arch. 1888;11:280–317.

    Google Scholar 

  11. Ransom W. Case of primary carcinoma of ileum. Lancet. 1890;136:1020–3.

    Google Scholar 

  12. Oberndorfer S. Karzinoide Rumoren des Dunndarms. Frankf. 1907;1:425–9.

    Google Scholar 

  13. Masson P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of the appendicular mucosa. Am J Pathol. 1928;4(3):181–212.

    PubMed  CAS  PubMed Central  Google Scholar 

  14. Page IH, Corcoran AC, Udenfriend S, Szoedsma A, Weissbach H. Argentaffinoma as endocrine tumour. Lancet. 1955;268(6856):198–9.

    PubMed  CAS  Google Scholar 

  15. Schnirer II, Yao JC, Ajani JA. Carcinoid – a comprehensive review. Acta Oncol. 2003;42(7):672–92.

    PubMed  Google Scholar 

  16. Komminoth P, Arnold R, Capella C. Neuroendocrine neoplasms of the appendix. 4th ed. Lyon: IARC2010; 2010. p. 217–24.

    Google Scholar 

  17. Hsu C, Rashid A, Xing Y, et al. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol. 2013;107(2):136–43.

    PubMed  Google Scholar 

  18. McGory ML, Maggard MA, Kang H, O’Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48(12):2264–71.

    PubMed  Google Scholar 

  19. Chejfec G, Falkmer S, Askensten U, Grimelius L, Gould VE. Neuroendocrine tumors of the gastrointestinal tract. Pathol Res Pract. 1988;183(2):143–54.

    PubMed  CAS  Google Scholar 

  20. Moore K, Dalley AF, Agur AM. The developing human. Clinically oriented embryology. 7th ed. W.B. Saunders Company; 2013. 1982. p. 226–46. Saint Louis, Missouri.

    Google Scholar 

  21. Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg. 1996;20(2):183–8.

    PubMed  CAS  Google Scholar 

  22. Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25(1):79–83.

    PubMed  CAS  Google Scholar 

  23. Hanson MW, Feldman JM, Blinder RA, Moore JO, Coleman RE. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology. 1989;172(3):699–703.

    PubMed  CAS  Google Scholar 

  24. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506.

    PubMed  CAS  Google Scholar 

  25. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875–82.

    PubMed  CAS  Google Scholar 

  26. Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.

    PubMed  CAS  Google Scholar 

  27. Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol. 2011;13(3):583–93.

    PubMed  Google Scholar 

  28. Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol. 2001;12 Suppl 2:S73–7.

    PubMed  Google Scholar 

  29. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685–90.

    PubMed  CAS  Google Scholar 

  30. Eriksson B. Tumor markers for pancreatic endocrine tumors, including chromogranins, HCG-alpha and HCG-beta. Basel: Karger; 1995. p. 121.

    Google Scholar 

  31. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J. 1995;71(839):542–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  32. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.

    PubMed  Google Scholar 

  33. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    PubMed  Google Scholar 

  34. Sobin LH, Gospodarowicz M, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Chichester: Wiley/Blackwell; 2009. p. 94–100.

    Google Scholar 

  35. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–62.

    PubMed  CAS  Google Scholar 

  36. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103(3):729–32.

    PubMed  CAS  Google Scholar 

  37. Löllgen RM, Hessman O, Szabo E, Westin G, Akerström G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer. 2001;92(6):812–5.

    PubMed  Google Scholar 

  38. Oberg K. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors). Curr Opin Endocrinol Diabetes Obes. 2009;16(1):72–8.

    PubMed  Google Scholar 

  39. Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg. 2003;90(11):1317–22.

    PubMed  CAS  Google Scholar 

  40. Syracuse DC, Perzin KH, Price JB, Wiedel PD, Mesa-Tejada R. Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. Ann Surg. 1979;190(1):58–63.

    PubMed  CAS  PubMed Central  Google Scholar 

  41. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on cancer (IARC); 2010. p. 13.

    Google Scholar 

  42. Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16(3):885–94.

    PubMed  CAS  Google Scholar 

  43. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1502–22.

    PubMed  CAS  Google Scholar 

  44. Kvols LK, Moertel CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315(11):663–6.

    PubMed  CAS  Google Scholar 

  45. Eriksson B, Renstrup J, Imam H, Oberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997;8(10):1041–4.

    PubMed  CAS  Google Scholar 

  46. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998;93(9):1468–71.

    PubMed  CAS  Google Scholar 

  47. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111.

    PubMed  CAS  Google Scholar 

  48. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23(4):412–5.

    PubMed  CAS  Google Scholar 

  49. Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14(5):557–60.

    PubMed  CAS  Google Scholar 

  50. Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30(7):733–40.

    PubMed  CAS  Google Scholar 

  51. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.

    PubMed  CAS  Google Scholar 

  52. Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90(6):687–93.

    PubMed  Google Scholar 

  53. Faiss S, Pape UF, Böhmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689–96.

    PubMed  CAS  Google Scholar 

  54. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94(5):1381–7.

    PubMed  CAS  Google Scholar 

  55. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–71.

    PubMed  CAS  Google Scholar 

  56. Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol. 1989;25(10):1475–9.

    PubMed  CAS  Google Scholar 

  57. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983;1(11):727–40.

    PubMed  CAS  Google Scholar 

  58. Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2(4):327–34.

    PubMed  CAS  Google Scholar 

  59. Eriksson BK, Larsson EG, Skogseid BM, Löfberg AM, Lörelius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83(11):2293–301.

    PubMed  CAS  Google Scholar 

  60. Nobin A, Månsson B, Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumour. Acta Oncol. 1989;28(3):419–24.

    PubMed  CAS  Google Scholar 

  61. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol. 1986;147(1):149–54.

    PubMed  CAS  Google Scholar 

  62. Diaco DS, Hajarizadeh H, Mueller CR, Fletcher WS, Pommier RF, Woltering EA. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg. 1995;169(5):523–8.

    PubMed  CAS  Google Scholar 

  63. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology. 1993;189(2):541–7.

    PubMed  CAS  Google Scholar 

  64. Kimmig BN. Radiotherapy for gastroenteropancreatic neuroendocrine tumors. Ann N Y Acad Sci. 1994;733:488–95.

    PubMed  CAS  Google Scholar 

  65. Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg. 1998;175(5):408–12.

    PubMed  CAS  Google Scholar 

  66. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer. 1993;71(8):2624–30.

    PubMed  CAS  Google Scholar 

  67. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17(7):474–8.

    PubMed  CAS  Google Scholar 

  68. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998;4(2):94–102.

    PubMed  CAS  Google Scholar 

  69. De Jong M, Breeman WA, Bernard HF, et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med. 1999;43(4):356–66.

    PubMed  Google Scholar 

  70. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32(2):123–32.

    PubMed  Google Scholar 

  71. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med. 2003;44(1):1–6.

    PubMed  CAS  Google Scholar 

  72. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–47.

    PubMed  CAS  Google Scholar 

  73. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32(2):148–55.

    PubMed  Google Scholar 

  74. Teunissen JJ, Kwekkeboom DJ, Krenning EP. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate. J Clin Oncol. 2004;22(13):2724–9.

    PubMed  CAS  Google Scholar 

  75. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S–6.

    PubMed  CAS  Google Scholar 

  76. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–23.

    PubMed  CAS  Google Scholar 

  77. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    PubMed  CAS  Google Scholar 

  78. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20(1):1–12.

    PubMed  Google Scholar 

  79. McCaughan BC, Martini N, Bains MS. Bronchial carcinoids. Review of 124 cases. J Thorac Cardiovasc Surg. 1985;89(1):8–17.

    PubMed  CAS  Google Scholar 

  80. Vuitch F, Sekido Y, Fong K, Mackay B, Minna JD, Gazdar AF. Neuroendocrine tumors of the lung. Pathology and molecular biology. Chest Surg Clin N Am. 1997;7(1):21–47.

    PubMed  CAS  Google Scholar 

  81. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119(6):1647–51.

    PubMed  CAS  Google Scholar 

  82. Scott WJ. Surgical treatment of other bronchial tumors. Chest Surg Clin N Am. 2003;13(1):111–28.

    PubMed  Google Scholar 

  83. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31(10):1255–65.

    PubMed  CAS  Google Scholar 

  84. Cardillo G, Sera F, Di Martino M, et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg. 2004;77(5):1781–5.

    PubMed  Google Scholar 

  85. Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17(4):909–18.

    PubMed  Google Scholar 

  86. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35(3):203–6.

    PubMed  CAS  Google Scholar 

  87. Borch K, Ahrén B, Ahlman H, Falkmer S, Granérus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005;242(1):64–73.

    PubMed  PubMed Central  Google Scholar 

  88. Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol. 2005;19(5):659–73.

    PubMed  CAS  Google Scholar 

  89. Campana D, Nori F, Pezzilli R, et al. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer. 2008;15(1):337–42.

    PubMed  CAS  Google Scholar 

  90. Klöppel G, Scherübl H. Neuroendocrine tumors of the stomach. Risk stratification and therapy. Pathologe. 2010;31(3):182–7.

    PubMed  Google Scholar 

  91. Akerström G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):87–109.

    PubMed  Google Scholar 

  92. Ruszniewski P, Delle Fave G, Cadiot G, et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006;84(3):158–64.

    PubMed  CAS  Google Scholar 

  93. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20(2):168–72.

    PubMed  CAS  Google Scholar 

  94. Eriksson B, Klöppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87(1):8–19.

    PubMed  CAS  Google Scholar 

  95. van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc. 2006;64(1):66–72.

    PubMed  Google Scholar 

  96. Johanssen S, Boivin M, Lochs H, Voderholzer W. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc. 2006;63(4):660–5.

    PubMed  Google Scholar 

  97. Bailey AA, Debinski HS, Appleyard MN, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol. 2006;101(10):2237–43.

    PubMed  Google Scholar 

  98. Bellutti M, Fry LC, Schmitt J, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009;54(5):1050–8.

    PubMed  Google Scholar 

  99. Akerström G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol. 1991;30(4):547–53.

    PubMed  Google Scholar 

  100. Rothmund M, Kisker O. Surgical treatment of carcinoid tumors of the small bowel, appendix, colon and rectum. Digestion. 1994;55 Suppl 3:86–91.

    PubMed  Google Scholar 

  101. Ahlman H, Wängberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion. 2000;62 Suppl 1:59–68.

    PubMed  Google Scholar 

  102. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14(3):377–83; discussion 384–375.

    PubMed  CAS  Google Scholar 

  103. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion. 1994;55 Suppl 3:98–103.

    PubMed  Google Scholar 

  104. Goede AC, Winslet MC. Surgery for carcinoid tumours of the lower gastrointestinal tract. Colorectal Dis. 2003;5(2):123–8.

    PubMed  CAS  Google Scholar 

  105. Sutton R, Doran HE, Williams EM, et al. Surgery for midgut carcinoid. Endocr Relat Cancer. 2003;10(4):469–81.

    PubMed  CAS  Google Scholar 

  106. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF. Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol. 2010;16(12):1527–32.

    PubMed  PubMed Central  Google Scholar 

  107. Norlén O, Hessman O, Stålberg P, Akerström G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg. 2010;34(6):1361–7.

    PubMed  Google Scholar 

  108. MacGillivray DC, Heaton RB, Rushin JM, Cruess DF. Distant metastasis from a carcinoid tumor of the appendix less than one centimeter in size. Surgery. 1992;111(4):466–71.

    PubMed  CAS  Google Scholar 

  109. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317(27):1699–701.

    PubMed  CAS  Google Scholar 

  110. Ryden SE, Drake RM, Franciosi RA. Carcinoid tumors of the appendix in children. Cancer. 1975;36(4):1538–42.

    PubMed  CAS  Google Scholar 

  111. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.

    PubMed  Google Scholar 

  112. Omohwo C, Nieroda CA, Studeman KD, et al. Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology. J Am Coll Surg. 2009;209(3):308–12.

    PubMed  Google Scholar 

  113. Jetmore AB, Ray JE, Gathright JB, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum. 1992;35(8):717–25.

    PubMed  CAS  Google Scholar 

  114. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794–803.

    PubMed  CAS  Google Scholar 

  115. Ballantyne GH, Savoca PE, Flannery JT, Ahlman MH, Modlin IM. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer. 1992;69(10):2400–5.

    PubMed  CAS  Google Scholar 

  116. Matsumoto T, Iida M, Suekane H, Tominaga M, Yao T, Fujishima M. Endoscopic ultrasonography in rectal carcinoid tumors: contribution to selection of therapy. Gastrointest Endosc. 1991;37(5):539–42.

    PubMed  CAS  Google Scholar 

  117. Kwaan MR, Goldberg JE, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy. Arch Surg. 2008;143(5):471–5.

    PubMed  Google Scholar 

  118. Onozato Y, Kakizaki S, Iizuka H, Sohara N, Mori M, Itoh H. Endoscopic treatment of rectal carcinoid tumors. Dis Colon Rectum. 2010;53(2):169–76.

    PubMed  Google Scholar 

  119. Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RC. A proposed staging system for rectal carcinoid tumors based on an analysis of 4701 patients. Surgery. 2008;144(3):460–6.

    PubMed  Google Scholar 

  120. Shields CJ, Tiret E, Winter DC, Group IRCS. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010;252(5):750–5.

    PubMed  Google Scholar 

  121. Sauven P, Ridge JA, Quan SH, Sigurdson ER. Anorectal carcinoid tumors. Is aggressive surgery warranted? Ann Surg. 1990;211(1):67–71.

    PubMed  CAS  PubMed Central  Google Scholar 

  122. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–76.

    PubMed  CAS  Google Scholar 

  123. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1):36–42; discussion 42–33.

    PubMed  CAS  Google Scholar 

  124. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572–81.

    PubMed  Google Scholar 

  125. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141(10):1000–4; discussion 1005.

    PubMed  Google Scholar 

  126. Le Treut YP, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225(4):355–64.

    PubMed  PubMed Central  Google Scholar 

  127. Gedaly R, Daily MF, Davenport D, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146(8):953–8.

    PubMed  Google Scholar 

  128. Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16(2):585–97.

    PubMed  Google Scholar 

  129. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187(1):88–92; discussion 92–83.

    PubMed  CAS  Google Scholar 

  130. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003;12(1):231–42.

    PubMed  Google Scholar 

  131. Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133(4):375–82.

    PubMed  Google Scholar 

  132. Srirajaskanthan R, Ahmed A, Prachialias A, et al. ENETS TNM staging predicts prognosis in small bowel neuroendocrine tumours. ISRN Oncol. 2013;2013:420795.

    PubMed  PubMed Central  Google Scholar 

  133. Godwin JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer. 1975;36(2):560–9.

    PubMed  Google Scholar 

  134. MacGillivray DC, Synder DA, Drucker W, ReMine SG. Carcinoid tumors: the relationship between clinical presentation and the extent of disease. Surgery. 1991;110(1):68–72.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, University of Michigan Hospital and Health Systems, 1500 East Medical Center Drive, 2920 Taubman Center, 48109-5331, Ann Arbor, MI, USA

    Christopher N. Scipione M.D. & Mark S. Cohen M.D.

Authors
  1. Christopher N. Scipione M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark S. Cohen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark S. Cohen M.D. .

Editor information

Editors and Affiliations

  1. Department of Surgery, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA

    Quyen D. Chu

  2. Department of Surgery, Jersey Shore University Medical Center, Neptune, New Jersey, USA

    John F. Gibbs

  3. John C. McDonald Regional Transplant Center, Willis Knighton Health System, Shreveport, Louisiana, USA

    Gazi B. Zibari

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Scipione, C.N., Cohen, M.S. (2015). Carcinoid Tumors. In: Chu, Q., Gibbs, J., Zibari, G. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1423-4_26

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1423-4_26

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1422-7

  • Online ISBN: 978-1-4939-1423-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation